logo
logo
Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

NASDAQ•AMLX
CEO: Mr. Joshua B. Cohen
セクター: Healthcare
業種: Biotechnology
上場日: 2022-01-07
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
連絡先情報
43 Thorndike Street, Cambridge, MA, 02141, United States
617-682-0917
amylyx.com
時価総額
$1.17B
PER (TTM)
-8.8
33.3
配当利回り
--
52週高値
$17.49
52週安値
$2.60
52週レンジ
77%
順位43Top 50.7%
3.8
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 3.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00-100.00%
直近4四半期の推移

EPS

-$0.37-65.42%
直近4四半期の推移

フリーCF

-$30.39M-26.86%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Loss Significantly Reduced Nine-month net loss narrowed 58% to $111.7M, driven by zero product revenue/cost of sales post-discontinuation.
Operating Expenses Decline Sharply SG&A expenses dropped 51% to $47.5M for nine months, reflecting wind-down of commercial operations for ALS product.
Strong Capital Raised Recently Financing provided $257.2M net cash in nine months, including $190.7M from September 2025 offering.
R&D Focus Shifts to Pipeline R&D spending decreased 15% to $69.2M, prioritizing Avexitide Phase 3 trial costs over discontinued ALS program.

リスク要因

Pipeline Success Highly Uncertain Business heavily depends on successful late-stage trials and regulatory approvals for Avexitide and AMX0035 candidates.
Requires Substantial Future Funding Expect significant losses and require substantial additional capital to fund ongoing development efforts into 2028.
Ongoing Legal Proceedings Risk Defending against putative class action and derivative lawsuits; impact estimate cannot currently be determined.
Macroeconomic Volatility Threatens Geopolitical instability and capital market disruption could negatively impact financing ability and operational continuity.

見通し

Avexitide Phase 3 Data Expected Expect topline data from pivotal LUCIDITY trial for Avexitide in PBH in the third quarter of 2026.
Advance AMX0035 Pivotal Trial Plan to initiate focused, pivotal Phase 3 trial for AMX0035 in Wolfram syndrome in the second half of 2026.
AMX0114 Early Data Forthcoming Anticipate presenting early cohort data from LUMINA Phase 1 trial for AMX0114 in ALS in December 2025.
Expect Increased R&D Expenses Expect R&D expenses to increase near term due to planned clinical development activities for pipeline assets.

同業比較

売上高 (TTM)

CureVac N.V.CVAC
$567.02M
-5.9%
Syndax Pharmaceuticals, Inc.SNDX
$111.55M
+597.2%
Wave Life Sciences Ltd.WVE
$109.23M
+103.7%

粗利益率 (最新四半期)

Immatics N.V.IMTX
100.0%
+0.0pp
Nektar TherapeuticsNKTR
100.0%
+18.4pp
Atai Life Sciences N.V.ATAI
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
WVE$2.34B-17.6-75.6%8.2%
SYRE$2.10B-17.5-31.2%0.0%
IMNM$2.06B-8.9-87.2%1.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月3日
|
EPS:-$0.30
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $0.00-100.0%
    |
    EPS: $-0.37-65.4%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $0.00-100.0%
    |
    EPS: $-0.46-57.0%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $0.00-100.0%
    |
    EPS: $-0.42-76.0%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月4日|
    売上高: $87.37M-77.1%
    |
    EPS: $-4.43-706.8%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $416.00K-99.6%
    |
    EPS: $-1.07-445.2%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: -$1.02M-101.0%
    |
    EPS: $-1.07-424.2%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月9日|
    売上高: $88.64M+24.1%
    |
    EPS: $-1.75-7515.3%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月22日|
    売上高: $380.79M+1612.9%
    |
    EPS: $0.73+124.5%
    予想を上回る